Posted in | News | Uranium

Macusani Yellowcake Reports Additional Assay Results from Chilcuno Chico Anomaly

Macusani Yellowcake has reported further drilling results from the Chilcuno Chico anomaly, located at the Kihitian property, Peru. These assay results is continuing to expand the "A" zone and the Manto "B" zone. The company has intersected 1,448 ppm U3O8 over 9 m, including 2,597 ppm U3O8 over 4.0 m.

Chilcuno Chico drill holes

The CEO and President of the company, has commented that the reported assay results have continued to show the depth and strike continuity at the Kihitian targets. These current results along with the released former drilling results have shown the possibility of high-grade uranium at the Kihitian’s large mineral resource.

The company has intersected 2,597 ppm U3O8 over 4.00 m in the hole PT-CH2-TSW, 717 ppm U3O8 over 2.00 m and 260 ppm U3O8 over 6.00 m in the hole PT-CH2-TNE, 679 ppm U3O8 over 7.00 m and 299 ppm U3O8 over 20.00 m in the hole PT-CH3-TSE, 405 ppm U3O8 over 7.00 m and 194 ppm U3O8 over 18.00 m in the hole PT-CH7-TV, 4,492 ppm U3O8 over 2.00 m and 1,535 ppm U3O8 over 6.00 m in the hole PT-CH8-TV, 2,236 ppm U3O8 over 7.00 m and 622 ppm U3O8 over 28.00 m in the hole PT-CH9-TSW, and 289 ppm U3O8 over 4.00 m in the hole PT-CH10-TSE.

Currently, Macusani is working with three drilling rigs at the property, which has also included the recently moved drill rig at the Quebrada Blanca anomaly that is 2 km to the NW of Chilcuno Chico. It is expecting the release of further assay results at the earliest and stays on target to announce a primary NI 43-101 resource estimate for the property before this year end.

Joel Scanlon

Written by

Joel Scanlon

Joel relocated to Australia in 1995 from the United Kingdom and spent five years working in the mining industry as an exploration geotechnician. His role involved utilizing GIS mapping and CAD software. Upon transitioning to the North Coast of NSW, Australia, Joel embarked on a career as a graphic designer at a well-known consultancy firm. Subsequently, he established a successful web services business catering to companies across the eastern seaboard of Australia. It was during this time that he conceived and launched News-Medical.Net. Joel has been an integral part of AZoNetwork since its inception in 2000. Joel possesses a keen interest in exploring the boundaries of technology, comprehending its potential impact on society, and actively engaging with AI-driven solutions and advancements.

Citations

Please use one of the following formats to cite this article in your essay, paper or report:

  • APA

    Scanlon, Joel. (2019, February 18). Macusani Yellowcake Reports Additional Assay Results from Chilcuno Chico Anomaly. AZoMining. Retrieved on November 21, 2024 from https://www.azomining.com/News.aspx?newsID=5161.

  • MLA

    Scanlon, Joel. "Macusani Yellowcake Reports Additional Assay Results from Chilcuno Chico Anomaly". AZoMining. 21 November 2024. <https://www.azomining.com/News.aspx?newsID=5161>.

  • Chicago

    Scanlon, Joel. "Macusani Yellowcake Reports Additional Assay Results from Chilcuno Chico Anomaly". AZoMining. https://www.azomining.com/News.aspx?newsID=5161. (accessed November 21, 2024).

  • Harvard

    Scanlon, Joel. 2019. Macusani Yellowcake Reports Additional Assay Results from Chilcuno Chico Anomaly. AZoMining, viewed 21 November 2024, https://www.azomining.com/News.aspx?newsID=5161.

Tell Us What You Think

Do you have a review, update or anything you would like to add to this news story?

Leave your feedback
Your comment type
Submit

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.